The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Gilles Vassal

Clinical and Translational Research

UPRES EA3535 Pharmacology and New Targets for Cancer

Institut Gustave-Roussy

Université Paris-SUD

France

[email]@igr.fr

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Clinical and Translational Research, UPRES EA3535 Pharmacology and New Targets for Cancer, Institut Gustave-Roussy, Université Paris-SUD, France. 2009
  • Department of Paediatrics, Institute Gustave Roussy, Villejuif, France. 2003 - 2008
  • Department of Paediatric Oncology, France. 2005
  • Laboratory of Pharmacotoxicology and Pharmacogenetics (CNRS URA147), Institut Gustave-Roussy, Villejuif, France. 1997 - 2003

References

  1. Will children with cancer benefit from the new European Paediatric Medicines Regulation?. Vassal, G. Eur. J. Cancer (2009) [Pubmed]
  2. A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). Vassal, G., Giammarile, F., Brooks, M., Geoerger, B., Couanet, D., Michon, J., Stockdale, E., Schell, M., Geoffray, A., Gentet, J.C., Pichon, F., Rubie, H., Cisar, L., Assadourian, S., Morland, B. Eur. J. Cancer (2008) [Pubmed]
  3. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. Vassal, G., Couanet, D., Stockdale, E., Geoffray, A., Geoerger, B., Orbach, D., Pichon, F., Gentet, J.C., Picton, S., Bergeron, C., Cisar, L., Assadourian, S., Morland, B. J. Clin. Oncol. (2007) [Pubmed]
  4. Has chemotherapy reached its limits in pediatric cancers?. Vassal, G. Eur. J. Cancer (2005) [Pubmed]
  5. In vivo antitumor activity of S16020, a topoisomerase II inhibitor, and doxorubicin against human brain tumor xenografts. Vassal, G., Merlin, J.L., Terrier-Lacombe, M.J., Grill, J., Parker, F., Sainte-Rose, C., Aubert, G., Morizet, J., Sévenet, N., Poullain, M.G., Lucas, C., Kalifa, C. Cancer Chemother. Pharmacol. (2003) [Pubmed]
  6. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. Vassal, G., Doz, F., Frappaz, D., Imadalou, K., Sicard, E., Santos, A., O'Quigley, J., Germa, C., Risse, M.L., Mignard, D., Pein, F. J. Clin. Oncol. (2003) [Pubmed]
  7. Clinical trials in paediatric oncology. Recommendations for the development of new anticancer agents. Vassal, G., Méry-Mignard, D., Caulin, C. Therapie (2003) [Pubmed]
  8. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. Vassal, G., Boland, I., Terrier-Lacombe, M.J., Watson, A.J., Margison, G.P., Vénuat, A.M., Morizet, J., Parker, F., Lacroix, C., Lellouch-Tubiana, A., Pierre-Kahn, A., Poullain, M.G., Gouyette, A. Clin. Cancer Res. (1998) [Pubmed]
  9. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Vassal, G., Boland, I., Santos, A., Bissery, M.C., Terrier-Lacombe, M.J., Morizet, J., Sainte-Rose, C., Lellouch-Tubiana, A., Kalifa, C., Gouyette, A. Int. J. Cancer (1997) [Pubmed]
 
WikiGenes - Universities